249 related articles for article (PubMed ID: 33044559)
1. [Alopecia areata with good response to tofacitinib].
Maksimow A; Stintzing D; Wohlrab J
Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
3. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Brown L; Skopit S
J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Cheng MW; Kehl A; Worswick S; Goh C
J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
9. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population.
AlMarzoug A; AlOrainy M; AlTawil L; AlHayaza G; AlAnazi R; AlIssa A; AlSheikh A; AlKhalifah A; AlHarithy R
Int J Dermatol; 2022 Jul; 61(7):886-894. PubMed ID: 34716573
[TBL] [Abstract][Full Text] [Related]
10. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
Erduran F; Adışen E; Aksakal AB
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
12. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Liu LY; Craiglow BG; King BA
J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
[No Abstract] [Full Text] [Related]
14. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis.
Putterman E; Castelo-Soccio L
J Am Acad Dermatol; 2018 Jun; 78(6):1207-1209.e1. PubMed ID: 29754888
[No Abstract] [Full Text] [Related]
15. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
[No Abstract] [Full Text] [Related]
16. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran.
Asilian A; Mohammadian P; Shahmoradi Z
J Cosmet Dermatol; 2024 Mar; 23(3):886-890. PubMed ID: 37933534
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Husein-ElAhmed H; Abdulla N; Al-Obaidli A; Ali-Alam M; Steinhoff M
Dermatol Ther; 2022 Dec; 35(12):e15871. PubMed ID: 36177791
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Dincer D; Tanacan E; Kose Ozkan C
J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
[TBL] [Abstract][Full Text] [Related]
20. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Salman A; Sarac G; Ergun T
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
